A case-only analysis of the interaction between N-acetyltransferase 2 haplotypes and tobacco smoke in breast cancer etiology

Breast Cancer Research

Volumn 7, Issue 3, 2005, Pages

  Lash, Timothy L ^a,b   Bradbury, Brian D ^a,c   Wilk, Jemma B ^b   Aschengrau, Ann ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; TOBACCO SMOKE; CARCINOGEN; NAT2 PROTEIN, HUMAN;

ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; NAT2 GENE; PRIMARY TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; VERY ELDERLY; YOUNG ADULT; ACETYLATION; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; INDOOR AIR POLLUTION; METABOLISM; RISK FACTOR; SMOKING;

ACETYLATION; ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CARCINOGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; RISK FACTORS; SMOKING; TOBACCO SMOKE POLLUTION;

EID: 33644789458     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1013     Document Type: Article

References (43)

1. Phillips DH: DNA adducts in human tissues: biomarkers of exposure to carcinogens in tobacco smoke. Environ Health Perspect. 1996, 453-458.
2. Vineis P, Caporaso N: Tobacco and cancer: epidemiology and the laboratory. Environ Health Perspect. 1995, 103: 154-156.
3. Hein DW: Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988, 948: 37-66.
4. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000, 9: 29-42.
5. Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol. 1990, 9: 193-203.
6. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002, 30: 65-77.
7. Grant DM, Blum M, Demierre A, Meyer UA: Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res. 1989, 17: 3978-
8. Evans DA: N-acetyltransferase. Pharmacol Ther. 1989, 42: 157-234. 10.1016/0163-7258(89)90036-3.
9. Blum M, Demierre A, Grant DM, Heim M, Meyer UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci. 1991, 88: 5237-5241.
10. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993, 14: 1633-1638.
11. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995, 57: 581-592.
12. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, Shields PG: Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996, 276: 1494-1501. 10.1001/jama.276.18.1494.
13. Ambrosone CB, Shields PG: Molecular epidemiology of breast cancer. Prog Clin Biol Res. 1997, 396: 83-99.
14. van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, Bueno de Mesquita HB: NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics. 2003, 13: 399-407. 10.1097/00008571-200307000-00005.
15. Millikan RC, Pittman GS, Newman B, Tse CK, Selmin O, Rockhill B, Savitz D, Moorman PG, Bell DA: Cigarette smoking, N-Acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 7: 371-378.
16. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, Manson JE, Colditz GA, Willett WC, Speizer FE, et al: A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis. 1997, 18: 2127-2132. 10.1093/carcin/18.11.2127.
17. Terry PD, Rohan TE: Cigarette smoking and the risk of breast cancer in women: A review of the literature. Cancer Epidemiol Biomarkers Prev. 2002, 11: 953-71.
18. Palmer J, Rosenberg L: Cigarette smoking and the risk of breast cancer. Epidemiol Rev. 1993, 15: 145-156.
19. Morabia A, Bernstein M: A review of the relation of smoking (active and passive) and breast cancer. J Women's Cancer. 2000, 2: 1-9.
20. Morabia A, Bernstein M, Heritier S, Khatchatrian N: Relation of breast cancer with passive and active exposure to tobacco smoke. Am J Epidemiol. 1996, 143: 918-928.
21. Smith SJ, Deacon JM, Chilvers CED: Alcohol, smoking, passive smoking and caffeine in relation to breast cancer risk in young women. Br J Cancer. 1994, 70: 112-119.
22. Lash TL, Aschengrau A: Active and passive cigarette smoking and the occurrence of breast cancer. Am J Epidemiol. 1999, 149: 5-12.
23. Johnson KC, Hu J, Mao Y: Passive and active smoking and breast cancer risk in Canada, 1994-97. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control. 2000, 11: 211-221. 10.1023/A:1008906105790.
24. Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A: Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002, 11: 698-704.
25. Morabia A, Bernstein MS, Bouchardy I, Kurtz J, Morris MA: Breast cancer and active and passive smoking: The role of the N-acetyltransferase 2 genotype. Am J Epidemiol. 2000, 152: 226-232. 10.1093/aje/152.3.226.
26. Aschengrau A, Roger S, Ozonoff D: Perchloroethylene-contaminated drinking water and the risk of breast cancer: additional results from Cape Cod, Massachusetts, USA. Environ Health Perspect. 2003, 111: 167-173.
27. Silliman RA, Guadagnoli E, Rakowski W, Landrum MB, Lash TL, Wolf R, Fink A, Ganz PA, Gurwitz J, Borbas C, et al: Adjuvant tamoxifen prescription in women 65 years and older with early stage breast cancer. J Clin Oncol. 2002, 20: 2680-1688. 10.1200/JCO.2002.08.137.
28. Deguchi T: Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem. 1992, 267: 18140-18147.
29. Blum M, Demierre A, Grant DM, Heim M, Meyers UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA. 1991, 88: 5237-5241.
30. Vatsis KP, Martell KJ, Weber WW: Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA. 1991, 88: 6333-6337.
31. Ohsako S, Deguchi T: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferase from human liver. J Biol Chem. 1990, 265: 4630-4634.
32. Cascorbi I, Brockmoller J, Bauer S, Reum T, Roots I: NAT2*12A (803→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics. 1996, 6: 257-259.
33. Lin HJ, Han CY, Lin BK, Hardy S: Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics and whites: application to metabolic epidemiology. Am J Hum Genet. 1993, 52: 827-834.
34. Hickman D, Risch A, Camilleri JP, Sim E: Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics. 1992, 2: 217-226.
35. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993, 14: 1689-1692.
36. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, et al: Genetically based N-acetyltransferase metabolic polymorphisms and low-level environmental exposure to carcinogens. Nature. 1994, 369: 154-156. 10.1038/369154a0.
37. SAS Institute Inc: SAS. Version 8. 1999, Cary, NC: SAS Institute
38. Colditz GA, Frazier AL: Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995, 4: 567-571.
39. Russo J, Russo IH: Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994, 3: 353-364.
40. Greenland S: The effect of misclassification in the presence of covariates. Am J Epidemiol. 1980, 112: 564-569.
41. Clayton D, McKeigue PM: Epidemiologic methods for studying genes and environmental factors in complex diseases. Lancet. 2001, 358: 1356-1360. 10.1016/S0140-6736(01)06418-2.
42. Greenland S, Rothman KJ: Concepts of interaction. Modern Epidemiology. Edited by: Rothman K, Greenland S. 1998, Philadelphia, PA: Lippincott-Raven, 332-336. 2
43. Albert PS, Ratnasignghe D, Tangrea J, Wacholder S: Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol. 2001, 154: 687-693. 10.1093/aje/154.8.687.